Pimecrolimus
| Evidence Level: L2 | Predicted Indications: 4 |
Table of Contents
Pimecrolimus: From Atopic Dermatitis to Seborrheic Dermatitis
One-Sentence Summary
Pimecrolimus is a topical calcineurin inhibitor originally developed and marketed internationally (as Elidel) for atopic dermatitis, but it currently holds no marketing registration in this jurisdiction. The TxGNN model predicts it may also be effective for Seborrheic Dermatitis, with 1 clinical trial and 18 publications currently supporting this direction, largely reflecting well-established off-label use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Atopic Dermatitis (internationally approved use; see note below — no local registration record exists) |
| Predicted New Indication | Seborrheic Dermatitis |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L2 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Note on Original Indication: This candidate’s source regulatory dataset shows zero local licenses and no
original_moaon file — the drug has never been registered in this market. Its internationally recognized indication (atopic dermatitis, marketed as Elidel) is cited here for mechanistic context only, not as a locally verified label claim.
Why is This Prediction Reasonable?
Detailed local mechanism-of-action documentation is not available (data gap), but pharmacological literature consistently describes pimecrolimus as a topical, cell-selective calcineurin inhibitor. It suppresses T-cell activation and blocks release of inflammatory cytokines (IL-2, IL-4, interferon-γ, TNF-α), and also inhibits mast cell degranulation — this is the mechanism underlying its established use in atopic dermatitis.
Seborrheic dermatitis and atopic dermatitis are both chronic, relapsing inflammatory skin conditions with overlapping T-cell-mediated cytokine pathways; seborrheic dermatitis additionally involves Malassezia yeast-triggered keratinocyte and T-cell inflammation. Because calcineurin inhibition dampens the shared inflammatory cascade rather than targeting a disease-specific driver, the mechanistic extension from atopic dermatitis to seborrheic dermatitis is biologically plausible.
Critically, this is not a purely theoretical hypothesis: topical pimecrolimus has been used off-label for seborrheic dermatitis in clinical practice since the mid-2000s, and this usage is corroborated by two independent systematic reviews of RCTs showing efficacy comparable to corticosteroids and antifungal agents, with a favorable side-effect profile for long-term/facial use.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00403559 | Phase 2 | Completed | 113 | Randomized, double-blind, parallel-group, active-comparator-controlled exploratory study of Elidel (pimecrolimus) for seborrheic dermatitis. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22142161 | 2012 | Systematic Review of RCTs | Expert Rev Clin Pharmacol | Pimecrolimus 1% cream is a well-tolerated, effective treatment for seborrheic dermatitis with efficacy comparable to corticosteroids/antimycotics. |
| 34910320 | 2022 | RCT (vs sertaconazole) | Clin Exp Dermatol | Randomized blinded trial comparing pimecrolimus 1% cream vs. sertaconazole 2% cream for facial seborrhoeic dermatitis. |
| 23715821 | 2013 | RCT (vs sertaconazole) | Ir J Med Sci | Compared efficacy of sertaconazole 2% cream vs. pimecrolimus 1% cream in treatment of seborrheic dermatitis. |
| 36072203 | 2022 | Systematic Review | Cureus | Critical review of efficacy and safety of pimecrolimus in facial seborrheic dermatitis across RCTs, positioned among calcineurin-inhibitor treatment options. |
| 23441238 | 2013 | Clinical Study/Review | J Clin Aesthet Dermatol | Topical pimecrolimus offers a safe long-term alternative to corticosteroids for seborrheic dermatitis, avoiding steroid-related adverse effects. |
| 20000875 | 2010 | Open-label Study | Am J Clin Dermatol | Pimecrolimus 1% cream effective and well tolerated in resistant facial seborrheic dermatitis. |
| 28589618 | 2018 | Clinical Study | J Cosmet Dermatol | Compared different treatment-duration regimens of pimecrolimus 1% cream for facial seborrheic dermatitis. |
| 19391059 | 2010 | Clinical Study | J Dermatolog Treat | Evaluated safe, effective repetitive/long-term use of pimecrolimus in relapsing seborrheic dermatitis. |
| 19255921 | 2009 | Clinical Study | J Dermatolog Treat | Close follow-up study reporting mean cure/remission times and side-effect profile of pimecrolimus in seborrheic dermatitis. |
| 15700745 | 2004 | Clinical Study | Drugs Exp Clin Res | Early study assessing efficacy, tolerability and safety of pimecrolimus cream 1% for seborrheic dermatitis of face and trunk. |
Safety Considerations
- Drug Interactions: A DDInter query identified 103 total documented interacting drugs; however, severity levels are marked “Unknown” (unclassified) in the source data for all entries reviewed. Frequently listed interacting agents include: Phentermine, Pantoprazole, Doxycycline, Metformin, Omeprazole, Lansoprazole, Triamcinolone, Prednisone, Simvastatin, Nystatin, Hydrocortisone, Tetracycline, Ranitidine, Ondansetron, Metronidazole, Famotidine, Acetylsalicylic acid, Rabeprazole, Bupropion, and Budesonide. Given the “Unknown” severity classification, clinical significance cannot be determined from this data alone — please cross-check against the product label.
Key warnings and contraindications are not available in the current dataset; please refer to the package insert for this information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The seborrheic dermatitis signal is supported by a completed Phase 2 RCT and a coherent body of literature (2 tier-1 systematic reviews, 2 tier-1 head-to-head RCTs, plus multiple supporting clinical studies spanning 2004–2022), and reflects mechanistically plausible, long-standing off-label practice rather than a purely novel hypothesis. However, this candidate carries a Blocking-severity data gap (DG001: local product-label warnings/contraindications), which per the evaluation framework prevents full entry into the S1 safety review — the “Proceed with Guardrails” status should be treated as conditional until this gap is closed.
To proceed, the following is needed:
- Obtain and parse the official product label (warnings, contraindications) — currently blocking (DG001)
- Obtain confirmed mechanism-of-action documentation from DrugBank (DG002)
- Reclassify the 103 DDI entries currently marked “Unknown” severity for clinical significance
- Given zero existing local registrations, confirm the regulatory pathway (new drug application vs. supplemental indication) required to bring pimecrolimus to market locally before pursuing the seborrheic dermatitis indication
- Note: the “dermatitis” (atopic dermatitis) prediction in this pack largely reflects validation of pimecrolimus’s existing global indication rather than a new repurposing signal, and should not be conflated with the seborrheic dermatitis opportunity above
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.